OmicsX Information

OmicsX builds decision operating systems that turn evidence into governed permission for biotech teams. We create structured decision products for DAC, ADC, target selection, vendor evaluation, CMC truth verification, clinical advancement, and portfolio risk governance, so teams know what is ready to advance, what must stay constrained, and what should stop. Instead of just delivering reports, we design the operating logic that governs high-consequence biotech choices across: ✔️ DAC Decision OS – Target logic, CMC, dose/BAD optimization, clinical governance, risk-to-capital progression ✔️ ADC Decision Systems – Payload, linker, translational proof, development gating ✔️ Target Decision OS – Modality fit, development readiness, investment quality ✔️ Vendor Selection OS – CDMO, CRO, assay, diagnostics partner evaluation ✔️ CMC Truth Systems – Functional sameness, drift detection, regulator-defensible handoffs ✔️ Portfolio & Capital Decision Logic – Prioritization, risk containment, funding gates Our systems convert evidence into explicit permission, constraints, and downstream consequences, ensuring CMC, clinical, regulatory, capital, and BD teams all operate from identical truth states. Built for biotech founders & CEOs, CSOs & platform leaders, CMC/development operators, clinical/translational heads, and specialist investors who need operator-grade clarity for expensive advancement decisions. Built on 15+ years of proprietary biotech intelligence across oncology, neurology, ADCs, TPDs/DACs, and emerging modalities, now structured as governed decision architecture rather than static reports. Our decision systems inherit insights from 6,000+ drug developers and 2,500+ CROs, delivering pattern recognition at operating system scale. Most biotech programs don't fail from lack of data. They fail when confidence moves faster than proof. Signal becomes permission. Handoffs lose constraints. Capital funds interpretation drift. OmicsX systems prevent that failure mode.